Three-child policy open-children's drug market ushered in development opportunities.

Three-child policy open-Children's drug market ushered in development opportunities

5Month31On the same day, the Political Bureau of the CPC Central Committee held a meeting and released heavy news: through the implementation of the policy that a couple can have three children and supporting measures, in order to improve China's population structure, implement the national strategy of actively coping with the aging population, and maintain the advantages of human resources endowment.

Undoubtedly, regardless of the opening of the three-child policyWill it bring birth climaxAll will bring a certain degree of development opportunities to the children's drug market. But at the same time, the children's drug market is also facing great challenges.

For a long time, because the research and development of children's drugs is one of the areas with the largest investment, the longest time-consuming and the most complex clinical trials in all drug research and development, and the scope of application of children's drugs is narrow, drug manufacturers need to bear huge research and development risks and low cash returns. There is no effective balance between the two, and pharmaceutical companies are not enthusiastic about the development of children's drugs, resulting in relatively lagging development of children's drugs.

According to incomplete statistics, as2021Year6Month, China's domestic drugs total.149787Article approval, while children's drug-related approval3000About, only accounting2%. Among them, from the type of division, children's drug approvals to Chinese medicine-based, accounting for nearly70%. In all categories of drugs, the highest proportion of children's drugs were respiratory system drugs, digestive system drugs and anti-infective drugs.

Therefore, the face of children's drug market enterprises lack the plight of continuous innovation power.In recent years, the state has issued a series of policies, technical requirements, and guidelines to encourage the development of drugs for children.

As early as the 12th meeting of the Standing Committee of the 13th National People's Congress, the newly revised Drug Administration Law was voted and passed, which clearly stipulates that effective measures should be taken to encourage the development and innovation of children's drugs, and support the development of children's physiological characteristics. New varieties, dosage forms and specifications of drugs for use, give priority to review and approval of drugs for children.

In addition, in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog" issued by the National Medical Insurance Administration, children's drugs are the new categories that are given priority coverage.

5Month31On the 15th, the Drug Evaluation Center of the State Drug Administration (CDE) announced6Month1Day opening“Children's Medication Column”In addition, policies and regulations, guiding principles and training materials related to children's medication will be made public in a centralized manner.

At present, the scale of China's children's drug market has reached1500Billion yuan, only accounting for the pharmaceutical industry5%. However, in terms of population size, children account16.6%The market space for children's medication is still huge. Predictably,“three children”Policies continue to land, drug review and approval, health insurance policies and other encouraging tilt in children's drug research and development, children's drug market will usher in unprecedented development opportunities. The industry is expected,2021The size of the market for such drugs may exceed2000billion, and continue to maintain an average annual growth rate of more than double digits.